Literature DB >> 27696414

Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2.

Mark Schiffman1, Kai Yu1, Rosemary Zuna2, S Terence Dunn3, Han Zhang1, Joan Walker3, Michael Gold4, Noorie Hyun1, Greg Rydzak5, Hormuzd A Katki1, Nicolas Wentzensen1.   

Abstract

A challenge in implementation of sensitive HPV-based screening is limiting unnecessary referrals to colposcopic biopsy. We combined two commonly recommended triage methods: partial HPV typing and "reflex" cytology, evaluating the possibility of automated cytology. This investigation was based on 1,178 exfoliated cervical specimens collected during the enrollment phase of The Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED, Oklahoma City, OK). We chose a colposcopy clinic population to maximize number of outcomes, for this proof-of-principle cross-sectional study. Residual aliquots of PreservCyt were HPV-typed using Linear Array (LA, Roche Molecular Systems, Pleasanton, CA). High-risk HPV typing data and cytologic results (conventional and automated) were used jointly to predict risk of histologically defined ≥CIN2. We developed a novel computer algorithm that uses the same optical scanning features that are generated by the FocalPoint Slide Profiler (BD, Burlington, NC). We used the Least Absolute Shrinkage and Selection Operator (LASSO) method to build the prediction model based on a training dataset (n = 600). In the validation set (n = 578), for triage of all HPV-positive women, a cytologic threshold of ≥ASC-US had a sensitivity of 0.94, and specificity of 0.30, in this colposcopy clinic setting. When we chose a threshold for the severity score (generated by the computer algorithm) that had an equal specificity of 0.30, the sensitivity was 0.91. Automated cytology also matched ≥ASC-US when partial HPV typing was added to the triage strategy, and when we re-defined cases as ≥CIN3. If this strategy works in a prospective screening setting, a totally automated screening and triage technology might be possible.
© 2016 UICC.

Entities:  

Keywords:  HPV; automation; cancer; cervical; cytology; screening

Mesh:

Year:  2016        PMID: 27696414      PMCID: PMC5159264          DOI: 10.1002/ijc.30456

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: I. A prospective intended use study.

Authors:  S F Patten; J S Lee; D C Wilbur; T A Bonfiglio; T J Colgan; R M Richart; H Cramer; S Moinuddin
Journal:  Cancer       Date:  1997-12-25       Impact factor: 6.860

2.  Multiple biopsies and detection of cervical cancer precursors at colposcopy.

Authors:  Nicolas Wentzensen; Joan L Walker; Michael A Gold; Katie M Smith; Rosemary E Zuna; Cara Mathews; S Terence Dunn; Roy Zhang; Katherine Moxley; Erin Bishop; Meaghan Tenney; Elizabeth Nugent; Barry I Graubard; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Oncol       Date:  2014-11-24       Impact factor: 44.544

3.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Authors:  Susanne K Kjær; Kirsten Frederiksen; Christian Munk; Thomas Iftner
Journal:  J Natl Cancer Inst       Date:  2010-09-14       Impact factor: 13.506

4.  Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.

Authors:  Thomas C Wright; Mark H Stoler; Catherine M Behrens; Abha Sharma; Guili Zhang; Teresa L Wright
Journal:  Gynecol Oncol       Date:  2015-01-08       Impact factor: 5.482

5.  Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

Authors:  Julia C Gage; Mark Schiffman; Hormuzd A Katki; Philip E Castle; Barbara Fetterman; Nicolas Wentzensen; Nancy E Poitras; Thomas Lorey; Li C Cheung; Walter K Kinney
Journal:  J Natl Cancer Inst       Date:  2014-07-18       Impact factor: 13.506

6.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Allan Hildesheim; Philip E Castle; Diane Solomon; Robert Burk
Journal:  J Natl Cancer Inst       Date:  2008-03-25       Impact factor: 13.506

7.  Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.

Authors:  Nicolas Wentzensen; Mark Schiffman; Terence Dunn; Rosemary E Zuna; Michael A Gold; Richard A Allen; Roy Zhang; Mark E Sherman; Sholom Wacholder; Joan Walker; Sophia S Wang
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

8.  Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany.

Authors:  Karl Ulrich Petry; Alexander Luyten; Sarah Scherbring
Journal:  Gynecol Oncol       Date:  2012-10-23       Impact factor: 5.482

9.  Second edition of 'The Bethesda System for reporting cervical cytology' - atlas, website, and Bethesda interobserver reproducibility project.

Authors:  Ritu Nayar; Diane Solomon
Journal:  Cytojournal       Date:  2004-10-21       Impact factor: 2.091

10.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Authors:  Guglielmo Ronco; Joakim Dillner; K Miriam Elfström; Sara Tunesi; Peter J F Snijders; Marc Arbyn; Henry Kitchener; Nereo Segnan; Clare Gilham; Paolo Giorgi-Rossi; Johannes Berkhof; Julian Peto; Chris J L M Meijer
Journal:  Lancet       Date:  2013-11-03       Impact factor: 79.321

View more
  6 in total

1.  Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology.

Authors:  Kai Yu; Noorie Hyun; Barbara Fetterman; Thomas Lorey; Tina R Raine-Bennett; Han Zhang; Robin E Stamps; Nancy E Poitras; William Wheeler; Brian Befano; Julia C Gage; Philip E Castle; Nicolas Wentzensen; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

2.  Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.

Authors:  Megan A Clarke; Ana Gradissimo; Nicolas Wentzensen; Robert D Burk; Mark Schiffman; Jessica Lam; Christopher C Sollecito; Barbara Fetterman; Thomas Lorey; Nancy Poitras; Tina R Raine-Bennett; Philip E Castle
Journal:  Clin Cancer Res       Date:  2018-02-02       Impact factor: 12.531

3.  MicroRNAs as markers of progression in cervical cancer: a systematic review.

Authors:  Barbara Pardini; Daniela De Maria; Antonio Francavilla; Cornelia Di Gaetano; Guglielmo Ronco; Alessio Naccarati
Journal:  BMC Cancer       Date:  2018-06-27       Impact factor: 4.430

4.  Back from the Future: Rational Accountabilities for Cytopathology in Pap Test Cervical Cancer Screening Arising from Covid19.

Authors:  Nikolaos Chantziantoniou
Journal:  Acta Cytol       Date:  2022-01-28       Impact factor: 3.000

5.  HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.

Authors:  Mark H Stoler; Thomas C Wright; Valentin Parvu; Karen Yanson; Karen Eckert; Salma Kodsi; Charles Cooper
Journal:  Am J Clin Pathol       Date:  2019-03-01       Impact factor: 2.493

6.  A cross-sectional study exploring triage of human papillomavirus (HPV)-positive women by visual assessment, manual and computer-interpreted cytology, and HPV-16/18-45 genotyping in Cameroon.

Authors:  Pierre Vassilakos; Ania Wisniak; Rosa Catarino; Eveline Tincho Foguem; Christine Balli; Essia Saiji; Jean-Christophe Tille; Bruno Kenfack; Patrick Petignat
Journal:  Int J Gynecol Cancer       Date:  2021-04-08       Impact factor: 3.437

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.